2013 Corporate Goals for Strategic Leadership Team Approved by the Compensation Committee on April 29, 2013

EX-10.1 2 exhibit101.htm EXHIBIT Exhibit 10.1

Exhibit 10.1

*** Text Omitted and Filed Separately

Confidential Treatment Requested

Under 17 CFR §§240.24b-2

2013 Corporate Goals for Strategic Leadership Team

Approved by the Compensation Committee on April 29, 2013

Revenue and Operating Income (50)%

Revenues for the Year - 20%

Interpolation will be used.



Total Revenue Growth Vs. Prior Year	Funding	*Corresponding Unit Growth Rate
≥ [***]% growth	200%	[***]
≥ [***]% growth	175%	[***]
≥ [***]% growth	150%	[***]
≥ [*]% ([*])	125%	[***]
≥ [***]% growth	100%	[***]
≥ [***]% growth	75%	[***]
≥ [***]% growth	50%	[***]
≥ [***]% growth	25%	[***]
< [***]% growth	No Payout

* reference only not calculated in the funding

Q4 Revenue Implications - 20%

Interpolation will be used.

• Q4 2013 growth over Q4 2012 - $13.6 million



Q4 Total Revenue Growth Vs. Prior Year	Funding	Q4 Revenues
≥ [***]% growth	200%	[***]
≥ [***]% growth	175%	[***]
≥ [***]% growth	150%	[***]
≥ [***]% growth	125%	[***]
≥ [***]% growth	100%	[***]
≥ [***]% growth	75%	[***]
< [***]% growth	No Payout

Operating Income (millions) - 10%

Interpolation will be used.



Operating Income (Loss) [***]	Operating Loss +/-	Funding
([***])	60%	200%
([***])	70%	175%
([***])	80%	150%
([***])	90%	125%
([*]) target [*]	100%	100%
([***])	110%	75%
([***])	120%	50%
([***])	130%	25%
([***])	140%	No Payout

Managed Care (30%)

• 2 Commercial Plans (> [***] million lives in total) - 20%

○ +5% payout for each additional plan having > [***] million lives

○ e.g., 3 plans = 25% payout

• 8 Employer Conversions (> [***] lives each) - 5%

• 1 Major National Plan Win (or very high likelihood of coverage in the new year) - 5%

○ +5% if delivered by end of [***] (e.g., 10% payout)

○ +10% if delivered by end of [***] (e.g., 15% payout)

HDL-P (10%)

• FDA Clearance by the end of Q4

Compliance & Ethics (10%)

• 5% - meet the timely completion requirements of Sunshine Act

• 5% - no significant deficiency re: Adva Med Policy

[***] Certain confidential information in this document, marked by bracketed asterisks, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 promulgated under the Securities Exchange Act of 1934, as amended. Confidential treatment has been requested with respect to the omitted portions.